1. Assessment of Relative Tumor Burden in Patients With Clinical T1c Prostate Cancer Treated With Either External Beam or Radical Prostatectomy
- Author
-
Kagan Ar, Kaswick Ja, Hintz Bl, Murphy Js, Bellman Gc, and Ruel Cj
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Prostate cancer ,Prostate ,Biopsy ,medicine ,Carcinoma ,Humans ,Neoplasm Staging ,Retrospective Studies ,Prostatectomy ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,Radiotherapy Dosage ,Prostate-Specific Antigen ,medicine.disease ,Survival Analysis ,Surgery ,Radiation therapy ,Prostate-specific antigen ,medicine.anatomical_structure ,Oncology ,Transrectal ultrasonography ,business - Abstract
The choice between external beam radiation therapy (EBRT) or retropubic radical prostatectomy (RPX) as potentially curative treatment for localized carcinoma of the prostate gland (CaP) has not been delineated in randomized studies. Both treatments are more effective if tumor burden is low. We sought to compare these two treatments in patients who had clinical stage T1c (cT1c) lesions and who were thought to have limited tumor burdens pretreatment. Sixty cT1c patients referred to the Department of Radiation Oncology received 66 Gy in 33 sessions of EBRT to localized prostate ports and 59 cT1c patients had RPX. No neoadjuvant nor early adjuvant therapies were prescribed. Radiotherapy success was defined biochemically as a nonrising prostate-specific antigen (PSA) of +/- 1.5 ng/ml. RPX success required a postoperative PSA that was undetectable (PSA
- Published
- 1999